MedTrace Logo

Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer

NCT05869097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-05-22

No results posted yet for this study

Summary

This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020 to October 2022 at the Hunan Cancer Hospital.

Conditions

  • Metastatic Colorectal Adenocarcinoma

Interventions

DRUG

Trifluridine/Tipiracil

TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days

DRUG

Bevacizumab

Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-10-31
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05869097 on ClinicalTrials.gov